LONDON, May 22, 2001 (PRIMEZONE) -- Cambridge Drug Discovery Limited (Cambridge Drug Discovery) and Teijin Limited (Teijin), today announced that they have entered into a key collaborative agreement focused towards the identification of novel lead compounds for the treatment of inflammatory disorders. The collaboration is based on a discovery program already underway at Cambridge Drug Discovery and the new alliance follows on from the completion of a research project earlier this year. The current agreement represents the second alliance between Cambridge Drug Discovery and Teijin. Financial details were not disclosed
In the first phase of the program, Teijin will have access to Cambridge Drug Discovery's target and assay development technologies as well as the Company's fully automated high-throughput screening system and diverse compound library of "drug-like" molecules. The collaboration will initially be focused on the identification of lead candidates with an option to expand the collaboration leading to the discovery of clinical drug candidates with CDD providing lead optimization, chemistry and biology support.
Commenting on this new collaboration, Cambridge Drug Discovery's Chief Executive Officer, Dr. Mark Treherne said, "We are extremely pleased to build on our rewarding relationship and look forward to partnering this program with Teijin and continuing our successful working partnership. We are confident of identifying novel drugs for rapid pre-clinical development."
Dr. Atsushi Imaizumi, Director of Pharmaceutical Discovery Research Laboratories of Teijin, commented that, "We are very happy to start a new collaboration programme with CDD. Teijin and CDD will work very closely together to obtain drug-like lead molecules. This is the second Teijin/CDD project and we know each other very well, therefore, we are expecting not only the quality of the molecules, but also the speed of discovery."
Please click on link to view formatted version of press release.
Attachments: http://reports.huginonline.com/822077/90241.pdf
Please do not hesitate to contact Noonan Russo Ltd. if you have any questions or queries.